Sponsors & Partners
2026 conference
The 2026 Prader-Willi Research and Family Conference will be the year's landmark event, bringing together researchers, scientists, clinicians, families, and the wider disability and rare disease community.
The conference will showcase world-leading Australian research, highlight innovative clinical practices, and provide families with resources, workshops, and community connections. Alongside International plenary speakers, research symposiums, and a dedicated family program, the conference will feature special events including the Research Catalyst Dinner and a Cocktail Welcome Reception.
This is a unique opportunity to align your brand with groundbreaking research, clinical excellence, and a passionate, resilient community.
Current Sponsors & Partners
premier Sponsor
Brisbane Airport Conference Centre - located within the same precinct as the Pullman Hotel Brisbane Airport. It includes 1,800 square metres of dedicated conference, meeting and events space that can accommodate up to 300 people.
Brisbane Airport Conference Centre is the host for the 2026 Prader-Willi Research and Family Conference, Pathways Forward: Where Hope Ignites Innovation.
Champion Sponsor
About Aardvark Therapeutics, Inc.
Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome (PWS) and metabolic diseases. Hunger, which is the discomfort from not having eaten recently, is a distinct neural signaling pathway separate from appetite, the reward-seeking desire for food. Our programs explore therapeutic applications in hunger-associated indications and potential complementary uses with anti-appetite therapies. Our lead compound, oral ARD-101, is in Phase 3 clinical development for the treatment of hyperphagia associated with PWS, a rare disease characterized by insatiable hunger. Aardvark is also developing ARD-201, a planned fixed-dose combination of ARD-101 with a DPP-4 inhibitor, through two separate Phase 2 trials with a goal of addressing some of the limitations of currently marketed GLP-1 therapies for obesity and obesity-related conditions. For more information, visit www.aardvarktherapeutics.com.
Partner Sponsor
Bright Minds Biosciences is a clinical-stage neuroscience company developing highly selective serotonin 5-HT2 receptor agonists for central nervous system disorders. Using structure-based drug design, the company engineers compounds that retain the therapeutic benefit of serotonergic signaling while avoiding off-target activity and tolerability limitations that constrained earlier agents in this class.
Lead candidate BMB-101, a Gq-protein-biased 5-HT2C agonist, met its primary efficacy endpoints in both cohorts of the Phase 2 BREAKTHROUGH study in adults with drug-resistant epilepsy, delivering clinically meaningful seizure reduction with a favorable safety and tolerability profile. Preparations for global registrational trials in absence seizures and developmental and epileptic encephalopathies are under way.
Bright Minds is also developing 5-HT2C agonists for Prader-Willi syndrome, a rare genetic disorder in which hyperphagia and behavioral disturbance drive severe morbidity and caregiver burden, with no approved therapy addressing the whole spectrum of symptoms of the disease. 5-HT2C receptors are expressed on hypothalamic POMC neurons central to satiety signaling, and the same pathway modulates impulsivity and affective regulation. BMB-101 is being evaluated in an exploratory Phase 2 study in Australia.
Additional 5-HT2 assets are advancing in pain and psychiatry, supported by a lean organization built for rapid clinical execution in areas of unmet need.
